PMID- 33946917
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210518
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 10
IP  - 9
DP  - 2021 Apr 29
TI  - Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in 
      Transcriptional Active Human Parvovirus B19-Positive Patients.
LID - 10.3390/jcm10091928 [doi]
LID - 1928
AB  - Human parvovirus B19 (B19V) is the predominant cardiotropic virus associated with 
      dilated inflammatory cardiomyopathy (DCMi). Transcriptionally active cardiotropic 
      B19V infection is clinically relevant and triggers adverse long-term mortality. 
      During the study; we evaluated whether antiviral treatment with the nucleoside 
      analogue telbivudine (LTD) is effective in suppressing transcriptional active 
      B19V in endomyocardial biopsies (EMBs) of B19V positive patients and improving 
      clinical outcomes. Seventeen B19V-positive patients (13 male; mean age 45.7 +/- 
      13.9 years; mean left ventricular ejection fraction (LVEF) 37.7 +/- 13.5%) with 
      positive B19V DNA and transcriptional activity (B19V mRNA) in EMBs were treated 
      with 600 mg/d LTD over a period of six months. Patients underwent EMBs before and 
      after termination of the LTD treatment. B19V RNA copy numbers remained unchanged 
      in 3/17 patients (non-responder) and declined or disappeared completely in the 
      remaining 14/17 patients (responder) (p </= 0.0001). Notably; LVEF improvement was 
      more significant in patients who reduced or lost B19V RNA (responder; p = 0.02) 
      in contrast to non-responders (p = 0.7). In parallel; responder patients 
      displayed statistically significant improvement in quality of life (QoL) 
      questionnaires (p = 0.03) and dyspnea on exertion (p = 0.0006), reflecting an 
      improvement in New York Heart Association (NYHA) Classification (p = 0.001). Our 
      findings demonstrated for the first time that suppression of B19V transcriptional 
      activity by LTD treatment improved hemodynamic and clinical outcome 
      significantly. Thus; the present study substantiates the clinical relevance of 
      detecting B19V transcriptional activity of the myocardium.
FAU - Schultheiss, Heinz-Peter
AU  - Schultheiss HP
AD  - Institute of Cardiac Diagnostics and Therapy, 12203 Berlin, Germany.
AD  - Department of Cardiology, Campus Benjamin Franklin, Charite-Universitatsmedizin 
      Berlin, 12200 Berlin, Germany.
FAU - Bock, Thomas
AU  - Bock T
AUID- ORCID: 0000-0002-2773-486X
AD  - Institute of Cardiac Diagnostics and Therapy, 12203 Berlin, Germany.
AD  - Institute of Tropical Medicine, University of Tubingen, 72074 Tubingen, Germany.
FAU - Pietsch, Heiko
AU  - Pietsch H
AUID- ORCID: 0000-0002-1661-159X
AD  - Institute of Cardiac Diagnostics and Therapy, 12203 Berlin, Germany.
AD  - Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, 
      Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), Berlin, Germany.
FAU - Aleshcheva, Ganna
AU  - Aleshcheva G
AD  - Institute of Cardiac Diagnostics and Therapy, 12203 Berlin, Germany.
FAU - Baumeier, Christian
AU  - Baumeier C
AD  - Institute of Cardiac Diagnostics and Therapy, 12203 Berlin, Germany.
FAU - Fruhwald, Friedrich
AU  - Fruhwald F
AD  - Department of Cardiology, Medical University Graz, 8036 Graz, Austria.
FAU - Escher, Felicitas
AU  - Escher F
AUID- ORCID: 0000-0003-0678-5681
AD  - Institute of Cardiac Diagnostics and Therapy, 12203 Berlin, Germany.
AD  - Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, 
      Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), Berlin, Germany.
LA  - eng
GR  - NCT02970227/Deutsche Forschungsgemeinschaft/
PT  - Journal Article
DEP - 20210429
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8125167
OTO - NOTNLM
OT  - dilated inflammatory cardiomyopathy
OT  - parvovirus B19
OT  - telbivudine
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/06 06:00
MHDA- 2021/05/06 06:01
PMCR- 2021/04/29
CRDT- 2021/05/05 01:03
PHST- 2021/03/16 00:00 [received]
PHST- 2021/04/24 00:00 [revised]
PHST- 2021/04/25 00:00 [accepted]
PHST- 2021/05/05 01:03 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/05/06 06:01 [medline]
PHST- 2021/04/29 00:00 [pmc-release]
AID - jcm10091928 [pii]
AID - jcm-10-01928 [pii]
AID - 10.3390/jcm10091928 [doi]
PST - epublish
SO  - J Clin Med. 2021 Apr 29;10(9):1928. doi: 10.3390/jcm10091928.